Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00VMA
|
||||
| Former ID |
DIB014504
|
||||
| Drug Name |
Vatreptacog alfa (activated)
|
||||
| Synonyms |
NN-1731; NNC-0078-0000-0007; Recombinant factor VIIa analog with mutations V158D/E296V/M298Q (bleeding disorders), Novo Nordisk
|
||||
| Indication | Bleeding [ICD9: 444, 453; ICD10:I74, I80-I82] | Phase 3 | [1] | ||
| Company |
Novo Nordisk A/S
|
||||
| Target and Pathway | |||||
| Target(s) | Coagulation factor VII | Target Info | Modulator | [2] | |
| KEGG Pathway | Complement and coagulation cascades | ||||
| PANTHER Pathway | Angiogenesis | ||||
| Blood coagulation | |||||
| PathWhiz Pathway | Coagulation | ||||
| Reactome | BMAL1:CLOCK,NPAS2 activates circadian gene expression | ||||
| Extrinsic Pathway of Fibrin Clot Formation | |||||
| Gamma-carboxylation of protein precursors | |||||
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | |||||
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | |||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | |||||
| Blood Clotting Cascade | |||||
| Formation of Fibrin Clot (Clotting Cascade) | |||||
| Circadian Clock | |||||
| Folate Metabolism | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01392547) Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors. U.S. National Institutes of Health. | ||||
| REF 2 | Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.